Annual CFF
-$151.00 K
-$33.00 K-27.97%
01 December 2023
Summary:
COSCIENS Biopharma annual cash flow from financing activities is currently -$151.00 thousand, with the most recent change of -$33.00 thousand (-27.97%) on 01 December 2023. During the last 3 years, it has fallen by -$20.62 million (-100.74%).CSCI Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$188.00 K
-$61.90 K-49.09%
01 September 2024
Summary:
COSCIENS Biopharma quarterly cash flow from financing activities is currently -$188.00 thousand, with the most recent change of -$61.90 thousand (-49.09%) on 01 September 2024. Over the past year, it has dropped by -$129.00 thousand (-218.64%).CSCI Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$468.10 K
-$129.00 K-38.04%
01 September 2024
Summary:
COSCIENS Biopharma TTM cash flow from financing activities is currently -$468.10 thousand, with the most recent change of -$129.00 thousand (-38.04%) on 01 September 2024. Over the past year, it has dropped by -$218.40 thousand (-87.46%).CSCI TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CSCI Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -28.0% | -218.6% | -87.5% |
| 3 y3 years | -100.7% | -263.6% | -88.0% |
| 5 y5 years | -100.0% | -138.6% | +15.4% |
CSCI Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -100.2% | -100.9% | -102.2% |
COSCIENS Biopharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$188.00 K(+49.1%) | -$468.10 K(+38.0%) |
| June 2024 | - | -$126.10 K(+75.4%) | -$339.10 K(+19.5%) |
| Mar 2024 | - | -$71.90 K(-12.4%) | -$283.80 K(+3.5%) |
| Dec 2023 | -$151.00 K(+28.0%) | -$82.10 K(+39.2%) | -$274.10 K(+9.8%) |
| Sept 2023 | - | -$59.00 K(-16.7%) | -$249.70 K(+9.0%) |
| June 2023 | - | -$70.80 K(+13.8%) | -$229.00 K(+38.0%) |
| Mar 2023 | - | -$62.20 K(+7.8%) | -$166.00 K(+3.4%) |
| Dec 2022 | -$118.00 K(-100.2%) | -$57.70 K(+50.7%) | -$160.60 K(-28.3%) |
| Sept 2022 | - | -$38.30 K(+391.0%) | -$223.90 K(-5.6%) |
| June 2022 | - | -$7800.00(-86.3%) | -$237.30 K(-11.1%) |
| Mar 2022 | - | -$56.80 K(-53.1%) | -$266.80 K(+10.6%) |
| Dec 2021 | $51.04 M(+149.4%) | -$121.00 K(+134.0%) | -$241.30 K(-3.1%) |
| Sept 2021 | - | -$51.70 K(+38.6%) | -$249.00 K(-4.2%) |
| June 2021 | - | -$37.30 K(+19.2%) | -$259.80 K(-16.1%) |
| Mar 2021 | - | -$31.30 K(-75.7%) | -$309.60 K(-13.6%) |
| Dec 2020 | $20.47 M(+425.8%) | -$128.70 K(+105.9%) | -$358.30 K(-7.3%) |
| Sept 2020 | - | -$62.50 K(-28.2%) | -$386.50 K(-4.0%) |
| June 2020 | - | -$87.10 K(+8.9%) | -$402.80 K(-2.9%) |
| Mar 2020 | - | -$80.00 K(-49.0%) | -$414.80 K(-19.3%) |
| Dec 2019 | $3.89 M(>+9900.0%) | -$156.90 K(+99.1%) | -$514.30 K(-7.1%) |
| Sept 2019 | - | -$78.80 K(-20.5%) | -$553.60 K(-13.9%) |
| June 2019 | - | -$99.10 K(-44.8%) | -$643.20 K(-2.7%) |
| Mar 2019 | - | -$179.50 K(-8.5%) | -$661.10 K(+9.1%) |
| Dec 2018 | $0.00(-100.0%) | -$196.20 K(+16.5%) | -$606.00 K(+0.2%) |
| Sept 2018 | - | -$168.40 K(+43.9%) | -$604.90 K(+18.6%) |
| June 2018 | - | -$117.00 K(-5.9%) | -$510.10 K(+111.3%) |
| Mar 2018 | - | -$124.40 K(-36.2%) | -$241.40 K(-1054.2%) |
| Dec 2017 | $8.03 M(-19.1%) | -$195.10 K(+165.1%) | $25.30 K(-84.0%) |
| Sept 2017 | - | -$73.60 K(-148.5%) | $158.10 K(-97.8%) |
| June 2017 | - | $151.70 K(+6.6%) | $7.05 M(+3.9%) |
| Mar 2017 | - | $142.30 K(-328.4%) | $6.79 M(+4.9%) |
| Dec 2016 | $9.92 M(-75.7%) | -$62.30 K(-100.9%) | $6.47 M(+2.8%) |
| Sept 2016 | - | $6.82 M(-6259.4%) | $6.29 M(-1135.8%) |
| June 2016 | - | -$110.70 K(-37.0%) | -$607.40 K(+112.0%) |
| Mar 2016 | - | -$175.60 K(-27.0%) | -$286.50 K(-144.0%) |
| Dec 2015 | $40.80 M(+67.5%) | -$240.50 K(+198.4%) | $650.90 K(-11.9%) |
| Sept 2015 | - | -$80.60 K(-138.3%) | $739.10 K(+29.6%) |
| June 2015 | - | $210.20 K(-72.4%) | $570.10 K(-29.2%) |
| Mar 2015 | - | $761.80 K(-600.2%) | $805.50 K(+70.5%) |
| Dec 2014 | $24.36 M(+2.7%) | -$152.30 K(-39.0%) | $472.50 K(-85.7%) |
| Sept 2014 | - | -$249.60 K(-156.0%) | $3.31 M(-15.3%) |
| June 2014 | - | $445.60 K(+3.9%) | $3.90 M(+10.6%) |
| Mar 2014 | - | $428.80 K(-84.0%) | $3.53 M(+6.4%) |
| Dec 2013 | $23.71 M(-2.1%) | $2.68 M(+676.4%) | $3.32 M(+376.2%) |
| Sept 2013 | - | $345.50 K(+386.6%) | $696.20 K(+95.7%) |
| June 2013 | - | $71.00 K(-67.2%) | $355.70 K(+73.6%) |
| Mar 2013 | - | $216.60 K(+243.3%) | $204.90 K(+385.5%) |
| Dec 2012 | $24.21 M(-37.2%) | $63.10 K(+1162.0%) | $42.20 K(-119.9%) |
| Sept 2012 | - | $5000.00(-106.3%) | -$212.10 K(+29.3%) |
| June 2012 | - | -$79.80 K(-248.1%) | -$164.10 K(-26.8%) |
| Mar 2012 | - | $53.90 K(-128.2%) | -$224.20 K(-12.6%) |
| Dec 2011 | $38.56 M(+48.1%) | -$191.20 K(-460.8%) | -$256.40 K(+134.8%) |
| Sept 2011 | - | $53.00 K(-137.9%) | -$109.20 K(-73.9%) |
| June 2011 | - | -$139.90 K(-744.7%) | -$417.90 K(+59.4%) |
| Mar 2011 | - | $21.70 K(-149.3%) | -$262.20 K(-17.4%) |
| Dec 2010 | $26.03 M | -$44.00 K(-82.8%) | -$317.30 K(-264.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | -$255.70 K(-1718.4%) | $192.80 K(-61.3%) |
| June 2010 | - | $15.80 K(-147.3%) | $498.50 K(-46.9%) |
| Mar 2010 | - | -$33.40 K(-107.2%) | $939.00 K(-12.2%) |
| Dec 2009 | $14.21 M(-1291.7%) | $466.10 K(+832.2%) | $1.07 M(+62.0%) |
| Sept 2009 | - | $50.00 K(-89.0%) | $660.50 K(+14.0%) |
| June 2009 | - | $456.30 K(+368.5%) | $579.20 K(+253.4%) |
| Mar 2009 | - | $97.40 K(+71.5%) | $163.90 K(+35.9%) |
| Dec 2008 | -$1.19 M(-9.3%) | $56.80 K(-281.5%) | $120.60 K(-84.1%) |
| Sept 2008 | - | -$31.30 K(-176.3%) | $756.50 K(-23.8%) |
| June 2008 | - | $41.00 K(-24.2%) | $993.00 K(-73.6%) |
| Mar 2008 | - | $54.10 K(-92.2%) | $3.76 M(+1.6%) |
| Dec 2007 | -$1.31 M(-84.7%) | $692.70 K(+237.6%) | $3.70 M(+22.8%) |
| Sept 2007 | - | $205.20 K(-92.7%) | $3.01 M(+9.2%) |
| June 2007 | - | $2.80 M(<-9900.0%) | $2.76 M(-2406.9%) |
| Mar 2007 | - | -$6400.00(-200.0%) | -$119.50 K(+206.4%) |
| Dec 2006 | -$8.57 M(-109.6%) | $6400.00(-113.4%) | -$39.00 K(-109.7%) |
| Sept 2006 | - | -$47.70 K(-33.6%) | $403.20 K(-19.5%) |
| June 2006 | - | -$71.80 K(-196.9%) | $501.00 K(-13.4%) |
| Mar 2006 | - | $74.10 K(-83.5%) | $578.20 K(-18.8%) |
| Dec 2005 | $88.92 M(+254.4%) | $448.60 K(+795.4%) | $712.00 K(+32.1%) |
| Sept 2005 | - | $50.10 K(+827.8%) | $539.00 K(-8.3%) |
| June 2005 | - | $5400.00(-97.4%) | $587.50 K(-3.4%) |
| Mar 2005 | - | $207.90 K(-24.6%) | $608.30 K(+51.8%) |
| Dec 2004 | $25.09 M(+67.5%) | $275.60 K(+179.5%) | $400.70 K(+36.5%) |
| Sept 2004 | - | $98.60 K(+276.3%) | $293.60 K(+14.3%) |
| June 2004 | - | $26.20 K(+8633.3%) | $256.90 K(-2.0%) |
| Mar 2004 | - | $300.00(-99.8%) | $262.20 K(+18.8%) |
| Dec 2003 | $14.98 M(-76.2%) | $168.50 K(+172.2%) | $220.70 K(+12.6%) |
| Sept 2003 | - | $61.90 K(+96.5%) | $196.00 K(+28.2%) |
| June 2003 | - | $31.50 K(-176.5%) | $152.90 K(+21.1%) |
| Mar 2003 | - | -$41.20 K(-128.7%) | $126.30 K(-24.1%) |
| Dec 2002 | $63.05 M(+574.3%) | $143.80 K(+664.9%) | $166.30 K(+155.8%) |
| Sept 2002 | - | $18.80 K(+283.7%) | $65.00 K(+263.1%) |
| June 2002 | - | $4900.00(-508.3%) | $17.90 K(-91.8%) |
| Mar 2002 | - | -$1200.00(-102.8%) | $217.00 K(-54.1%) |
| Dec 2001 | $9.35 M(-28.8%) | $42.50 K(-250.2%) | $472.90 K(-3.3%) |
| Sept 2001 | - | -$28.30 K(-113.9%) | $488.80 K(-6.4%) |
| June 2001 | - | $204.00 K(-19.9%) | $522.00 K(-10.6%) |
| Mar 2001 | - | $254.70 K(+336.1%) | $584.10 K(+9.0%) |
| Dec 2000 | $13.13 M(+7.6%) | $58.40 K(+1091.8%) | $535.90 K(-2.5%) |
| Sept 2000 | - | $4900.00(-98.2%) | $549.40 K(-10.4%) |
| June 2000 | - | $266.10 K(+28.9%) | $613.10 K(+27.0%) |
| Mar 2000 | - | $206.50 K(+187.2%) | $482.70 K(+74.8%) |
| Dec 1999 | $12.20 M(+1464.6%) | $71.90 K(+4.8%) | $276.20 K(-28.6%) |
| Sept 1999 | - | $68.60 K(-49.4%) | $386.80 K(-77.1%) |
| June 1999 | - | $135.70 K(>+9900.0%) | $1.69 M(+4.5%) |
| Mar 1999 | - | $0.00(-100.0%) | $1.61 M(-8.0%) |
| Dec 1998 | $779.90 K(-89.8%) | $182.50 K(-86.7%) | $1.75 M(-30.4%) |
| Sept 1998 | - | $1.37 M(+2061.1%) | $2.52 M(+75.7%) |
| June 1998 | - | $63.30 K(-55.1%) | $1.44 M(-128.2%) |
| Mar 1998 | - | $140.90 K(-85.2%) | -$5.08 M(-132.1%) |
| Dec 1997 | $7.62 M(-29.9%) | $950.60 K(+238.2%) | $15.86 M(+6.4%) |
| Sept 1997 | - | $281.10 K(-104.4%) | $14.91 M(+1.9%) |
| June 1997 | - | -$6.46 M(-130.6%) | $14.63 M(-30.6%) |
| Mar 1997 | - | $21.09 M | $21.09 M |
| Dec 1996 | $10.87 M | - | - |
FAQ
- What is COSCIENS Biopharma annual cash flow from financing activities?
- What is the all time high annual CFF for COSCIENS Biopharma?
- What is COSCIENS Biopharma annual CFF year-on-year change?
- What is COSCIENS Biopharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for COSCIENS Biopharma?
- What is COSCIENS Biopharma quarterly CFF year-on-year change?
- What is COSCIENS Biopharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for COSCIENS Biopharma?
- What is COSCIENS Biopharma TTM CFF year-on-year change?
What is COSCIENS Biopharma annual cash flow from financing activities?
The current annual CFF of CSCI is -$151.00 K
What is the all time high annual CFF for COSCIENS Biopharma?
COSCIENS Biopharma all-time high annual cash flow from financing activities is $88.92 M
What is COSCIENS Biopharma annual CFF year-on-year change?
Over the past year, CSCI annual cash flow from financing activities has changed by -$33.00 K (-27.97%)
What is COSCIENS Biopharma quarterly cash flow from financing activities?
The current quarterly CFF of CSCI is -$188.00 K
What is the all time high quarterly CFF for COSCIENS Biopharma?
COSCIENS Biopharma all-time high quarterly cash flow from financing activities is $21.09 M
What is COSCIENS Biopharma quarterly CFF year-on-year change?
Over the past year, CSCI quarterly cash flow from financing activities has changed by -$129.00 K (-218.64%)
What is COSCIENS Biopharma TTM cash flow from financing activities?
The current TTM CFF of CSCI is -$468.10 K
What is the all time high TTM CFF for COSCIENS Biopharma?
COSCIENS Biopharma all-time high TTM cash flow from financing activities is $21.09 M
What is COSCIENS Biopharma TTM CFF year-on-year change?
Over the past year, CSCI TTM cash flow from financing activities has changed by -$218.40 K (-87.46%)